MedTrace Logo

Feasibility Study of a Novel Subcutaneous Continuous Glucose Monitoring System in Diabetics

NCT06867965 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-03-10

No results posted yet for this study

Summary

Mono-centre, open label (unblinded). 8 patients + 2 potential replacements. Duration up to 9 weeks: up to 6 weeks screening (42 days), 2 weeks of treatment (14 days, depending on sensor functionality) and 1 week of follow up (7 days)

Conditions

Interventions

DEVICE

BellySense

BellySense is a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.

Sponsors & Collaborators

  • EyeSense GmbH

    lead INDUSTRY

Principal Investigators

  • Christoph Hasslacher, Prof. Dr. · Diabetesinstitut Heidelberg

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867965 on ClinicalTrials.gov